A practical guide for toxicologic pathologists, study directors, and lab informatics leads evaluating digital pathology infrastructure

‍

Toxicologic pathology is one of the most demanding environments in all of digital pathology. The slide volumes are large, the regulatory obligations are non-negotiable, the data lives for decades, and the workflows — primary reads, peer reviews, sponsor collaboration, multi-site studies — span organizations and time zones in ways that make purely local infrastructure impractical.

Labs that have made the shift to fully digital toxicologic pathology workflows consistently report meaningful gains: faster study completion, more efficient peer review, reduced logistical friction on distributed studies, and a compliance posture that's easier to maintain and demonstrate. But those gains depend on having the right image management infrastructure underneath them. The wrong IMS doesn't just fail to deliver those benefits — it actively creates new problems on top of the ones it was supposed to solve.

This article is for teams that are either evaluating a first IMS for toxicologic pathology workflows, or questioning whether the platform they're on is actually capable of meeting the demands of the work.

Why toxicologic pathology puts unique demands on an IMS

Most image management systems are designed with a generalized digital pathology workflow in mind. Toxicologic pathology workflows are not general — they have specific characteristics that stress-test IMS capabilities in ways other disciplines don't.

Volume. A single nonclinical toxicology study can produce thousands of slides. At high scanning resolutions, that translates to terabytes of image data per study — and studies accumulate over years and decades. An IMS that performs adequately at modest slide volumes may degrade significantly under the throughput and storage demands of a high-output tox lab.

Regulatory obligations. Nonclinical safety studies submitted to regulatory agencies must be conducted under Good Laboratory Practice (GLP) regulations, which in the United States include 21 CFR Part 11 requirements for electronic records and electronic signatures. These aren't soft requirements that can be addressed through policy alone — they require validated software systems with specific technical controls: audit trails, access controls, reason-for-change documentation, and the validation documentation to prove the system meets these standards. Not every IMS is built to meet them.

Study structure. Toxicologic pathology studies have a well-defined structure: animal groups, dose levels, tissue types, staining protocols, and study identifiers that provide the clinical context pathologists need while reviewing. An IMS that can't organize and surface this metadata cleanly forces pathologists to manage context manually — an inefficiency that compounds across thousands of slides.

Long-term data retention. GLP regulations require study data to be retained for extended periods — often decades. Image libraries that are impractical to store at scale, that degrade in accessibility over time, or that can't be archived cost-effectively become a long-term liability. Storage economics and archival architecture matter.

Distributed review. Modern toxicologic pathology workflows are rarely confined to a single site. Primary reads, peer reviews, and sponsor consultations routinely involve pathologists and stakeholders in different cities or countries. The IMS needs to support this distribution natively — not through workarounds.

The GLP compliance question: what it actually requires of your IMS

GLP compliance in a digital pathology context is often discussed in terms of individual features — audit trails, access controls, electronic signatures. These features matter, but understanding why they're required — and what "compliant" actually means in practice — is what separates an IMS that genuinely supports regulated workflows from one that claims compliance without being built for it.

The core principle underlying GLP and 21 CFR Part 11 is data integrity: the assurance that electronic records are accurate, complete, consistent, and trustworthy throughout their lifecycle. In a digital pathology context, this means:

Changes to study data must be traceable. Who accessed which images, when, and what they did — annotations created, modified, or deleted; study metadata changed; findings recorded — must be captured in a tamper-evident audit trail. This isn't optional documentation; it's the evidentiary record that a regulatory inspection or sponsor audit will examine.

Changes must be justified. When study data is modified after initial entry, the reason for that change must be recorded alongside the modification. This reason-for-change requirement ensures that the audit trail captures not just what happened, but why — providing the context that auditors need to evaluate data integrity.

Access must be controlled and appropriate. Role-based access controls need to operate at the study and case level, not just the system level. Pathologists should see the studies they're assigned to; study directors should have appropriate oversight; sponsors should access only their own data. The granularity of these controls directly affects the defensibility of your data integrity posture.

The system must be validated. Computer system validation (CSV) — demonstrating through documented testing that the system consistently performs its intended functions — is a regulatory requirement for systems used in GLP work. This includes Installation Qualification (IQ) and Operational Qualification (OQ) documentation. An IMS vendor that can provide these documents, or that supports your validation team in producing them, helps you save on costs via reduced time and effort. 

Archival must preserve integrity. Long-term data retention isn't just about storage capacity — it's about maintaining the accessibility and integrity of records over their full retention period. Archival solutions need to be validated, cost-effective, and designed to keep data accessible (not just stored) for the duration of the retention requirement.

The practical implication: when evaluating an IMS for GLP work, the question isn't "does this platform have audit trail features?" It's "is this platform architected to meet data integrity requirements, and can the vendor support our validation efforts?" Those are different questions with different answers.

→ For a detailed look at PathcoreFlow's GLP compliance capabilities, visit our GLP Technology page.

Primary reads and peer reviews: different workflows, different requirements

One of the most consequential distinctions in toxicologic pathology IMS selection is the difference between primary read workflows and peer review workflows — and what each one demands from the platform.

Primary reads are the initial pathology assessment of study slides, typically conducted by a study pathologist working through a structured set of tissues and staining types in a defined sequence. This is the highest-volume, most time-sensitive work in a tox study, and the IMS experience during primary read directly determines study throughput.

For primary reads, the IMS needs to deliver:

• High-performance image streaming that keeps pace with a pathologist working through hundreds or thousands of slides. Lag between slides is not a minor inconvenience — it's a throughput bottleneck that compounds across large studies.
• Efficient study navigation with keyboard shortcuts, slide sorting and filtering, and a viewer interface optimized for moving through structured tissue sets without friction.
• Metadata in context — animal IDs, dose groups, tissue types, and staining protocols visible alongside the image, without requiring the pathologist to navigate away from the viewer.
• GLP compliance infrastructure if the study is regulated — which for primary reads in nonclinical safety studies, it typically is.

Peer reviews serve a different function: a second pathologist independently reviews findings to confirm diagnostic accuracy, resolve discrepancies, or provide regulatory documentation of a qualified review. Peer review workflows are governed by different procedural requirements than primary reads, and their GLP compliance implications are different.

Specifically: peer review does not always require a GLP-validated system. The regulatory requirement for GLP compliance attaches to primary reads and the official study record — the peer review function, depending on how it's structured and documented in the study protocol, may be conducted outside the GLP-validated environment. This distinction has practical implications: labs and CROs that need to offer peer review services to sponsors on studies where they didn't conduct the primary read may be able to use a broader range of collaboration tools for that specific function.

For most organizations, however, the simplest and most defensible approach is a single IMS that handles both functions within a consistent compliance framework — eliminating the need to manage the distinction at the workflow level and ensuring that all study-related activity is captured in a single audit trail.

Distributed review and sponsor collaboration

Toxicologic pathology studies increasingly involve geographically distributed teams. A CRO in North America might conduct a study for a European biopharma sponsor whose pathologist wants to observe key tissue findings remotely. A multi-site organization might split primary reads across two locations, with peer review handled at a third. A sponsor's scientific advisors might need access to images for independent review without coming on-site.

These scenarios all require the same thing from an IMS: secure, performant remote access that works across organizations without friction.

"Without friction." This means that external collaborators — sponsors, peer reviewers, scientific advisors — can access images through a browser without installing specialized software on their end. It means that access controls are granular enough that a sponsor can see their study data without seeing anyone else's. It means that the collaboration features — annotations, comparisons, commenting — work for remote participants the same way they work for users on-site.

For CROs in particular, the quality of these collaboration capabilities is increasingly a differentiator in client relationships. The ability to offer a sponsor real-time, authenticated, browser-based access to study images — with a clean interface and reliable performance — is the kind of capability that gets remembered in client conversations and referenced in proposals.

Storage and archival: the long-term cost that's easy to underestimate

Toxicologic pathology generates data at scale and retains it for extended periods. The economics of this — the cost of storing petabytes of image data for twenty or thirty years while keeping it accessible and compliant — is a planning variable that many labs underestimate when they begin their digital pathology journey.

The key considerations:

• Volume-based pricing matters more than per-seat pricing at ToxPath scale. An IMS that prices storage by the terabyte with a clear, predictable model is fundamentally different from one that obscures storage costs behind platform fees or charges for egress. At petabyte scale, the difference in storage economics can represent a significant portion of total platform cost.
• Hierarchical storage management (HSM) is worth understanding. Not all image data needs to be stored at the same cost tier at the same time. Recently completed studies require fast, accessible storage. Studies completed years ago can typically be moved to lower-cost archival tiers without impacting day-to-day operations — as long as the system can retrieve them on demand when needed for regulatory submission or audit. An IMS with integrated HSM capabilities gives labs the ability to manage storage costs intelligently over time without sacrificing data accessibility.
• Archival infrastructure must be validated. Long-term retention of GLP study data isn't just a storage question — it's a data integrity question. The archival solution must maintain the integrity and accessibility of records over their full retention period, and that maintenance needs to be documented as part of the overall validation picture.

→ Learn more about PathcoreFlow's hierarchical storage management capabilities and how it offers affordable archival solutions for preclinical studies.

LIS and LIMS integration: the metadata backbone of a tox study

In toxicologic pathology, the image is only meaningful in context. A slide showing liver tissue from an animal in dose group 3 at week 13 of a 26-week study tells a very different story than the same morphology from a control animal — but only if the pathologist knows which slide they're looking at and what it represents.

That context lives in the Laboratory Information System (LIS) or LIMS — and getting it into the IMS efficiently is one of the most practically important integration challenges in digital tox workflows.

The ideal integration is bidirectional: study metadata flows from the LIS into the IMS when a study is initiated, so that scanned images are automatically organized into the correct study structure with the correct identifiers. Findings and annotations made during pathology review flow back to the LIS for inclusion in the study record and final report. The pathologist never has to manually enter metadata or switch systems to find study context.

In practice, integration maturity varies. Some IMS platforms offer validated, production-tested integrations with common LIS platforms — Instem Provantis is the most widely used in preclinical tox — while others support only CSV-based metadata import, which is functional but requires more manual process management. Understanding the depth and reliability of LIS integration, for your specific LIS platform, should be an early step in any IMS evaluation for toxicologic pathology.

What to look for when evaluating an IMS for toxicologic pathology

The evaluation criteria for a tox-focused IMS overlap with general enterprise IMS requirements — but with specific areas that deserve deeper scrutiny:

→ For the complete evaluation framework, see: The IMS Evaluation Checklist: What to Ask Before You Buy

The cost of the wrong infrastructure in a regulated environment

In most software decisions, the cost of a poor choice is measured in productivity and frustration. In a GLP environment, the cost can be more acute.

An audit trail that doesn't capture the right events, a validation package that doesn't meet regulatory standards, or a system that requires compensating controls to meet data integrity requirements — these aren't just operational inconveniences. They're findings in a regulatory inspection. They're questions in a sponsor audit. They're reasons a study might need to be repeated.

The labs that invest in GLP-validated IMS infrastructure from the beginning consistently report that the compliance overhead of their digital pathology program is lower — not higher — than it was on paper-based or hybrid workflows. The system handles the documentation that used to require manual effort, and the audit trail is always current, always complete, and always ready for inspection.

That outcome isn't automatic. It requires the right IMS, properly validated, in a workflow that's been designed to use its compliance capabilities. But it's reliably achievable — and it's one of the strongest arguments for treating the IMS selection as a strategic compliance decision, not just an IT procurement.

‍

Ready to see how PathcoreFlow supports GLP-compliant toxicologic pathology workflows?
Talk to a solutions expert →
Learn more about PathcoreFlow for ToxPath →
‍Explore PathcoreFlow's GLP compliance capabilities →

‍

This article is part of Pathcore's digital pathology resource hub. For related reading, see:

• Everything to Know About an Image Management System (IMS)
• Why Your IMS Choice Defines Your Digital Pathology Strategy
• The IMS Evaluation Checklist: What to Ask Before You Buy
• Should you build or buy your digital pathology IMS?

‍